PEOPLE - Osiris Therapeutics (US) forms new senior management team:
This article was originally published in Clinica
US company Osiris Therapeutics has formed a senior management team which will focus on the commercialisation of its adult stem cell products. It includes Dr Annemarie Moseley as senior vice-president of clinical and regulatory affairs; Dr Daniel Marshak, senior vice-president and chief scientific officer; John Coker, vice-president and chief financial officer, secretary and treasurer; Dr Stewart Craig, vice-president of development and operations; Dr Robert Deans, vice-president of applied research; Dr Stephen Gordon, vice-president of advanced technology management; and Kenneth Moseley, vice-president of patents and business development.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.